Rheumatoid Arthritis Medications
Disease-Modifying Antirheumatic Drugs (DMARDs)
- DMARDs are the cornerstone of RA treatment and work by suppressing the immune system to slow disease progression and prevent joint destruction. These medications typically take weeks to months to achieve full therapeutic effect, requiring patient education about delayed onset of action.
- Methotrexate is the first-line DMARD for RA, functioning as a folate antagonist that inhibits cell proliferation and has anti-inflammatory effects. Administered weekly (not daily) either orally or subcutaneously with typical doses ranging from 7.5-25 mg once weekly.
- Hydroxychloroquine (Plaquenil) alters immune function by affecting lysosomal activity and interfering with antigen presentation. Requires regular ophthalmologic exams due to risk of retinal toxicity with long-term use.
- Leflunomide (Arava) inhibits pyrimidine synthesis, affecting rapidly dividing cells including inflammatory cells. Requires monitoring of liver function tests and has a very long half-life requiring cholestyramine washout if rapid drug elimination is needed.
- Sulfasalazine combines anti-inflammatory (5-ASA) and antimicrobial (sulfapyridine) properties, often used in mild RA or as part of combination therapy. Regular CBC monitoring is needed due to risk of blood dyscrasias.
Key Points
- Methotrexate requires folate supplementation to reduce side effects and is contraindicated in pregnancy (Pregnancy Category X).
- All DMARDs require regular blood monitoring for potential hematologic, hepatic, and renal toxicities.
- DMARDs work slowly (weeks to months) compared to NSAIDs or corticosteroids which provide rapid symptom relief.
Always check for drug interactions when patients are on DMARDs, particularly with methotrexate which can have serious interactions with NSAIDs, trimethoprim, and probenecid.
DMARD Memory Aid: "My Slow Healing Lessons" - Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide
Biologic Response Modifiers
- TNF Inhibitors including adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), golimumab (Simponi), and certolizumab pegol (Cimzia) target tumor necrosis factor-alpha, a key inflammatory cytokine in RA. These medications are typically administered subcutaneously or intravenously at intervals ranging from weekly to monthly.
- IL-6 Receptor Antagonists such as tocilizumab (Actemra) and sarilumab (Kevzara) block interleukin-6 signaling, reducing systemic inflammation and joint damage. These agents can improve anemia of chronic disease and rapidly reduce acute phase reactants like CRP and ESR.
- T-Cell Costimulation Modulator abatacept (Orencia) prevents T-cell activation by binding to CD80/CD86 on antigen-presenting cells, interrupting the costimulatory signal needed for T-cell activation. Administered IV or subcutaneously and particularly useful in patients who have failed TNF inhibitors.
- B-Cell Depleting Therapy rituximab (Rituxan) targets CD20 on B cells, causing B-cell depletion and reducing autoantibody production. Administered as two IV infusions separated by two weeks, with courses repeated every 6-12 months as needed.
- IL-1 Receptor Antagonist anakinra (Kineret) blocks the activity of interleukin-1, requiring daily subcutaneous injections. Less commonly used than other biologics due to daily administration requirement and modest efficacy compared to alternatives.
Key Points
- All biologics increase risk of infections, particularly tuberculosis, fungal infections, and reactivation of hepatitis B; screening for latent TB and hepatitis is mandatory before starting therapy.
- Live vaccines are contraindicated while on biologic therapy due to immunosuppression.
- Biologics are often used in combination with methotrexate for synergistic effects and to reduce antibody formation against the biologic agent.
A 42-year-old female with severe RA has been prescribed adalimumab (Humira) after inadequate response to methotrexate. Before starting treatment, the nurse should ensure the patient has been screened for tuberculosis with a PPD skin test or interferon-gamma release assay and has completed a hepatitis panel. The nurse should educate the patient on proper subcutaneous injection technique, rotation of injection sites, and signs of infection to report immediately.
JAK Inhibitors
- Janus Kinase (JAK) Inhibitors including tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) are oral targeted synthetic DMARDs that block intracellular signaling pathways involved in immune cell activation. These medications offer the convenience of oral administration while providing efficacy similar to biologic agents.
- JAK inhibitors work by blocking multiple cytokine signaling pathways simultaneously, which can lead to rapid improvement in symptoms, often within the first 1-2 weeks of treatment. They have the advantage of oral administration but carry risks including increased thrombosis risk and potential for viral reactivation.
Key Points
- JAK inhibitors carry boxed warnings for serious infections, malignancy, thrombosis, and major adverse cardiovascular events.
- Patients should be monitored for lipid elevations, cytopenias, and liver enzyme abnormalities while on JAK inhibitors.
- Unlike biologics, JAK inhibitors have a short half-life, allowing for quicker clearance if adverse effects occur.
Corticosteroids
- Systemic Corticosteroids such as prednisone, methylprednisolone, and dexamethasone provide rapid anti-inflammatory effects through multiple mechanisms including inhibition of inflammatory mediators and immune cell function. In RA, they are typically used as bridge therapy until DMARDs take effect or for management of disease flares.
- Intra-articular Corticosteroids like triamcinolone acetonide and methylprednisolone acetate can be injected directly into affected joints to provide localized anti-inflammatory effects with fewer systemic side effects. Limited to 3-4 injections per year in a single joint due to potential cartilage damage with repeated injections.
Key Points
- Long-term systemic corticosteroid use causes numerous adverse effects including osteoporosis, hyperglycemia, hypertension, increased infection risk, adrenal suppression, and cataracts.
- Corticosteroids should be tapered gradually after prolonged use to prevent adrenal crisis.
- Patients on long-term corticosteroids should receive calcium and vitamin D supplementation for bone health and may require bisphosphonates for osteoporosis prevention.
Never abruptly discontinue corticosteroids in patients who have been on therapy for more than 1-2 weeks, as this may precipitate adrenal crisis. Always use the lowest effective dose for the shortest duration possible.
Osteoarthritis Medications
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Nonselective NSAIDs including ibuprofen, naproxen, and diclofenac inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing production of prostaglandins that mediate pain and inflammation. These medications provide symptomatic relief for OA but do not alter disease progression.
- COX-2 Selective NSAIDs such as celecoxib (Celebrex) preferentially inhibit COX-2 enzymes while sparing COX-1, potentially reducing gastrointestinal side effects compared to nonselective NSAIDs. Still carry cardiovascular risks similar to nonselective NSAIDs, particularly at higher doses or with prolonged use.
- Topical NSAIDs like diclofenac gel or patch provide local anti-inflammatory effects with minimal systemic absorption, making them useful for OA affecting superficial joints like knees and hands. Particularly beneficial in elderly patients or those with contraindications to oral NSAIDs.
Key Points
- NSAIDs can cause gastric irritation, ulceration, bleeding, renal impairment, and increased cardiovascular risk, particularly with long-term use.
- NSAIDs should be used cautiously in patients with hypertension, heart failure, renal impairment, or history of GI bleeding.
- Concomitant use of proton pump inhibitors (PPIs) is recommended for patients at high risk of GI complications taking oral NSAIDs.
Monitor for signs of GI bleeding (melena, hematemesis, abdominal pain) and renal dysfunction (edema, decreased urinary output) in patients taking NSAIDs. Use with extreme caution in patients on anticoagulants.
Acetaminophen
- Acetaminophen (Tylenol) provides analgesic and antipyretic effects through central mechanisms, with minimal anti-inflammatory activity. Considered first-line therapy for mild OA pain due to favorable safety profile, particularly in elderly patients or those with contraindications to NSAIDs.
- Maximum recommended dose is 3000mg/day (previously 4000mg/day), with lower doses recommended for elderly patients or those with hepatic impairment. Despite being available over-the-counter, acetaminophen carries significant hepatotoxicity risk at high doses or with chronic alcohol use.
Key Points
- Acetaminophen has minimal anti-inflammatory effects, making it less effective than NSAIDs for inflammatory pain but safer for long-term use.
- Hepatotoxicity is the major adverse effect, particularly with overdose or in patients with liver disease or chronic alcohol consumption.
- Many combination products contain acetaminophen, requiring careful monitoring of total daily dose to prevent unintentional overdose.
Intra-articular Therapies
- Hyaluronic Acid Derivatives (viscosupplementation) such as hylan G-F 20 (Synvisc), sodium hyaluronate (Hyalgan), and others are injected into osteoarthritic joints to supplement synovial fluid viscosity and elasticity. Typically administered as a series of 1-5 weekly injections, providing pain relief for 3-6 months in responsive patients.
- Corticosteroid Injections provide potent local anti-inflammatory effects and rapid pain relief, typically lasting 4-8 weeks. Used for acute flares of OA pain or when other therapies are insufficient, with frequency limited to 3-4 times yearly per joint.
Key Points
- Hyaluronic acid injections are most effective for mild to moderate knee OA and may delay the need for joint replacement in some patients.
- Post-injection flare can occur with both corticosteroid and hyaluronic acid injections, characterized by increased pain for 24-48 hours after the procedure.
- Septic arthritis is a rare but serious complication of intra-articular injections, requiring strict aseptic technique during administration.
A 68-year-old male with moderate knee OA has failed oral analgesics and is scheduled for a hyaluronic acid injection series. The nurse should educate the patient that full benefit may take 3-5 weeks to develop, temporary increased pain may occur after injection, and he should avoid strenuous activity for 48 hours after each injection. The patient should also understand that this treatment may need to be repeated in 6 months if effective.
Duloxetine
- Duloxetine (Cymbalta) is a serotonin and norepinephrine reuptake inhibitor (SNRI) FDA-approved for chronic musculoskeletal pain including OA. Works centrally by enhancing descending inhibitory pain pathways in the central nervous system, providing analgesic effects independent of its antidepressant action.
- Typically initiated at 30mg daily for one week, then increased to 60mg daily maintenance dose. Useful for patients with inadequate response to traditional analgesics or those with comorbid depression or anxiety.
Key Points
- Duloxetine should be tapered gradually when discontinuing to prevent withdrawal symptoms.
- Side effects include nausea, dry mouth, constipation, dizziness, fatigue, and potential for increased blood pressure.
- Contraindicated with MAOIs and use caution with other serotonergic medications due to risk of serotonin syndrome.
Topical Analgesics
- Capsaicin depletes substance P from peripheral sensory neurons, reducing pain signal transmission. Available in various concentrations (0.025%-0.1%) as creams, gels, or patches, requiring application 3-4 times daily with gradual onset of effect over 1-2 weeks of regular use.
- Lidocaine Patches (5%) provide local anesthetic effect and are applied directly over painful joints for up to 12 hours per day. Particularly useful for localized OA pain in superficial joints like the knee, hand, or wrist.
- Counterirritants containing menthol, camphor, or methyl salicylate (e.g., Bengay, Icy Hot) create sensations of heat or cold that distract from pain perception. These products work through gate control mechanisms and local vasodilation or vasoconstriction.
Key Points
- Capsaicin initially causes burning sensation that diminishes with continued use; patients should be warned to avoid eye contact and wash hands thoroughly after application.
- Topical analgesics provide localized effect with minimal systemic absorption, making them suitable for patients who cannot tolerate oral medications.
- Lidocaine patches should not be cut and maximum recommended is 3 patches simultaneously for no more than 12 hours per day.
Commonly Confused Medications
DMARDs vs. Biologics
| Feature |
Conventional DMARDs |
Biologic DMARDs |
| Administration |
Mostly oral |
Parenteral (SC or IV) |
| Onset of action |
Slow (weeks to months) |
Relatively rapid (days to weeks) |
| Target |
Broad immunosuppression |
Specific cytokines or cells |
| Cost |
Lower |
Higher |
| Monitoring |
Regular blood tests (CBC, LFTs, renal function) |
TB screening, hepatitis screening, plus monitoring for infections |
| Examples |
Methotrexate, hydroxychloroquine, sulfasalazine, leflunomide |
Adalimumab, etanercept, infliximab, rituximab, abatacept |
NSAIDs vs. Acetaminophen
| Feature |
NSAIDs |
Acetaminophen |
| Anti-inflammatory effect |
Yes |
Minimal |
| Mechanism |
COX inhibition |
Central action (exact mechanism unclear) |
| Major side effects |
GI bleeding, renal impairment, CV risk |
Hepatotoxicity |
| Use in OA |
More effective for inflammatory pain |
First-line for mild pain, safer long-term |
| Effect on platelets |
Inhibits platelet aggregation (except COX-2 selective) |
No effect on platelets |
TNF Inhibitors vs. Other Biologics
| Feature |
TNF Inhibitors |
Non-TNF Biologics |
| Target |
Tumor Necrosis Factor-alpha |
IL-6, T-cells, B-cells, IL-1, etc. |
| First-line biologic |
Yes, typically first biologic used |
Usually used after TNF failure |
| TB risk |
Higher |
Present but generally lower than TNF inhibitors |
| Examples |
Adalimumab, etanercept, infliximab |
Tocilizumab, abatacept, rituximab, anakinra |
| Demyelinating disease risk |
Contraindicated in multiple sclerosis |
Generally safer in patients with demyelinating disorders |
Memory Aid for Biologic Mechanisms:
- TNF inhibitors: Target Tumor necrosis factor (adalimumab, etanercept, infliximab)
- B-cell therapy: Banishes B-cells (rituximab)
- Abatacept: Affects Activation of T-cells
- IL-6 blockers: Inhibit Interleukin-6 (tocilizumab, sarilumab)
Common Pitfall: Failing to recognize that methotrexate for RA is dosed WEEKLY, not daily. Mistaken daily dosing can lead to fatal toxicity. Always verify frequency of methotrexate administration.
Study Tips & Administration Guidelines
Methotrexate Administration
- Verify weekly dosing schedule (not daily)
- Confirm folic acid supplementation (typically 1mg daily except on methotrexate day)
- Check recent CBC, liver function, and renal function before administration
- For subcutaneous administration, select appropriate injection site (abdomen, thigh)
- Educate patient to report signs of toxicity: mouth sores, severe nausea, diarrhea, easy bruising, or shortness of breath
- Remind patient to avoid alcohol consumption due to increased risk of hepatotoxicity
- Ensure patient understands pregnancy prevention requirements (Category X)
Methotrexate Side Effect Memory Aid: "MARROW"
- Mucositis (mouth sores)
- Alopecia
- Renal toxicity
- Rashes
- Organs (liver toxicity)
- WBC depression (bone marrow suppression)
Biologic Administration Tips
- Storage requirements: Most biologics require refrigeration (36-46°F/2-8°C) and protection from light. Allow prefilled syringes or pens to warm to room temperature (30-45 minutes) before injection for reduced discomfort.
- Injection technique: Rotate subcutaneous injection sites between thighs, abdomen (at least 2 inches from navel), and upper arms. Pinch skin fold and inject at 45-90 degree angle depending on needle length and patient's body habitus.
- Infusion reactions: For IV biologics like infliximab, monitor for infusion reactions (flushing, chest discomfort, dyspnea, hypotension). Premedication with acetaminophen, antihistamines, or corticosteroids may be ordered to reduce reaction risk.
Key Points
- Never administer live vaccines to patients on biologics due to immunosuppression.
- Hold biologic therapy if patient develops serious infection requiring antibiotics or hospitalization.
- Most biologics can be continued during minor infections or perioperatively, but specific guidelines vary by medication and procedure.
Patient Education Essentials
- Infection vigilance: Patients on immunosuppressive therapy should be educated to report fever, persistent cough, unusual infections, or wounds that won't heal promptly to their healthcare provider.
- Medication adherence: Emphasize the importance of continuing DMARDs even when feeling well, as these medications prevent disease progression and joint damage.
- Laboratory monitoring: Ensure patients understand the importance of regular blood tests to monitor for medication toxicity and disease activity.
Patients should be instructed to hold immunosuppressive medications if they develop signs of significant infection and contact their healthcare provider immediately. This is particularly important for biologics and JAK inhibitors.
Self-Assessment Checklist
Quick Check
Test Your Knowledge
- Which DMARD requires folate supplementation to reduce side effects?
- What screening test is mandatory before starting a TNF inhibitor?
- What is the maximum recommended daily dose of acetaminophen?
- Which medication for OA works by centrally modulating pain pathways through serotonin and norepinephrine reuptake inhibition?
- How frequently should methotrexate be administered for RA?